Double-blind, randomized, placebo-controlled, escalating multiple-dose, phase I trial to assess the safety, tolerability and pharmacokinetics of SIGA-246 as a single daily dose for 21 days in healthy, non-fasted volunteers.

Trial Profile

Double-blind, randomized, placebo-controlled, escalating multiple-dose, phase I trial to assess the safety, tolerability and pharmacokinetics of SIGA-246 as a single daily dose for 21 days in healthy, non-fasted volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Tecovirimat (Primary)
  • Indications Orthopoxvirus infections; Smallpox
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Apr 2010 Results published in Antimicrobial Agents and Chemotherapy.
    • 15 Sep 2009 Results presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
    • 06 Dec 2007 Status changed to completed in accordance with SIGA Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top